Company Overview and News

 
Tetra Bio-Pharma Accelerates its European Drug Registration Activities

2018-09-11 globenewswire
ORLEANS, Ontario, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it is accelerating the submission of a pre-marketing application for the registration of its cannabis drugs PPP001 and PPP005 under Directive 2001/83/EC of the European Parliament and of the Council.
TBPMF TBP GRPOF

 
Tetra Bio-Pharma Announces Record Date for Dividend-in-Kind of North Bud Farms Shares

2018-08-31 globenewswire
ORLEANS, Ontario, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that its board of directors has declared a dividend-in-kind (the “Dividend”) of 15,500,000 common shares (each a "North Bud Share") of North Bud Farms Inc. ("North Bud") owned by Tetra pro rata to the holders of record of outstanding common shares (each, a "Tetra Share") of Tetra (the "Shareholders of Record") as at September 7, 2018 (the “Dividend Record Date”).
TBPMF TBP GRPOF

98
The CannaGuide: Complete Cannabis Coverage - Aphria Part 1 - Full Operations, Partnerships, And Investments Overview

2018-08-23 seekingalpha - 6
Part 1 in the CannaGuide on Aphria covering the companies current operations, expansion plans, and strategic partnerships/investments.
ACBFF CGC TLRY TBPMF TWMJF ACB APH WEED LHSIF CNTTF APHQF TBP MSRT CNNRF GRPOF

1
Tetra Bio-Pharma Targets Rare Cancers in the United States

2018-08-23 globenewswire - 1
OTTAWA, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), today announced the submission of multiple applications for Orphan Drug Designation for cannabinoids to the U.S. Food and Drug Administration, for the treatment of various forms of rare cancers and ocular diseases. The applications align with Tetra’s strategy to develop cannabis prescription drug products for the treatment of several rare cancers and to expand its market exclusivity in the treatment of ocular diseases.
TBPMF TBP GRPOF

174
Neptune Technologies & Bioresources' (NEPT) CEO Jim Hamilton on Q1 2019 Results - Earnings Call Transcript

2018-08-15 seekingalpha - 5
Neptune Technologies & Bioresources, Inc. (NASDAQ:NEPT) Q1 2019 Earnings Conference Call August 15, 2018 8:00 AM ET
NEPT TBPMF TWMJF APO ACST WEED TBP CGC GRPOF

2
Health Canada Gives Green Light to Tetra Bio-Pharma’s Cannabis Vs. Fentanyl Trial

2018-08-09 globenewswire - 2
ORLEANS, Ontario, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that Health Canada has approved its protocol for a clinical trial investigating its PPP001 drug as an alternative to the opioid fentanyl in the management of breakthrough cancer pain. The clinical trial will be conducted by Montreal-based Santé Cannabis, a medical clinic and contract research organization specialized in clinical research for cannabis - based therapies.
TBPMF TBP GRPOF

1
Tetra Bio-Pharma’s Dr. Chamberland to Announce Health Canada’s Green Light for the Cannabis vs. Fentanyl Trial

2018-08-08 globenewswire - 1
ORLEANS, Ontario, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that Health Canada has approved its protocol for a clinical trial investigating its PPP001 drug as an alternative to the opioid fentanyl in the management of breakthrough cancer pain. Dr. Guy Chamberland, Interim CEO and Chief Scientific Officer will provide additional details on TVA’s Gatineau 6:00 p.
TBPMF TBP GRPOF

1
Tetra Bio-Pharma Provides Extension to North Bud Farms  

2018-08-03 globenewswire - 1
ORLEANS, Ontario, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that the company has provided an extension to North Bud Farms Inc. Tetra and North Bud Farms Inc. are working diligently to finalize the transaction and to this end Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc.
TBPMF TBP GRPOF

1
UPDATE -- Tetra Bio-Pharma Confirms Meetings With FDA

2018-07-26 globenewswire - 1
ORLEANS, Ontario, July 26, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF) today announced that it received two meeting granted letters from the United States Food and Drug Administration (FDA), for Type B and C meetings, to discuss requirements for obtaining marketing approval under the 505(b)(2) regulatory pathway for its dronabinol AdVersa™ mucoadhesive product, PPP002.
TBPMF TBP GRPOF

 
Tetra Bio-Pharma Confirms Meetings With FDA

2018-07-26 globenewswire
ORLEANS, Ontario, July 26, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF) today announced that it received two meeting granted letters from the United States Food and Drug Administration (FDA), for Type B and C meetings, to discuss requirements for obtaining marketing approval under the 505(b)(2) regulatory pathway for its dronabinol AdVersa™ mucoadhesive product, PPP002.
TBPMF TBP GRPOF

1
Tetra Natural Health Announces Upcoming Launch of Hemp Energy Drink

2018-07-19 globenewswire - 1
ORLEANS, Ontario, July 19, 2018 (GLOBE NEWSWIRE) -- Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), announced that it will be commercializing Hemp Energy Drink, a caffeinated energy drink containing hemp, that received a Temporary Marketing Authorization (TMA) by Health Canada. Tetra intends on launching this product ahead of the upcoming legalization as it begins to position itself as a player in the natural health product market.
TBPMF TBP GRPOF

2
Tetra Bio-Pharma Targets Multi-Billion Dollar Fibromyalgia Market

2018-07-16 globenewswire - 2
Co-development deal announced with Germany’s Storz & Bickel aims to improve delivery of cannabinoid-based pain relief
TBPMF TBP GRPOF

4
Tetra Bio-Pharma’s Evidence-Based Business Model Confirmed

2018-06-29 globenewswire - 1
ORLEANS, Ontario, June 29, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced that the amendment of the Prescription Drug List (PDL) to include phyto-cannabinoids supports its evidence-based business model. Since early 2016 Tetra’s product development and commercialization strategy followed the exact same pathway as that used in the development of prescription drugs, namely rigorous, independently validated scientific evidence.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Adds a New Leader for its Commercial Operations

2018-06-19 globenewswire
ORLEANS, Ontario, June 19, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Mr. Richard Giguere has been hired as Executive Vice-President, Commercial Operations. He will be responsible for the commercial sales and operations of Tetra Natural Health and Tetra Veterinary Health.
TBPMF TBP GRPOF

3
Tetra Bio-Pharma Takes on Fentanyl in Head to Head Trial for the Treatment of Breakthrough Pain

2018-06-18 globenewswire
ORLEANS, Ontario, June 18, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Santé Cannabis, the independently credentialed research organization they work with has finalized the clinical study protocol evaluation of PPP001, which will be the first time that cannabis is being compared to fentanyl in a clinical trial.
TBPMF TBP GRPOF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 39985Y102